Motley Fool Premium
  1. Stocks
    2. /
  2. AstraZeneca Plc (LSE: AZN)
    3. /

LSE:AZN (AstraZeneca Plc)

About AZN

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Financial Market Data copyright © 2026 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

AstraZeneca Plc (LSE: AZN) Latest News

Cargo containers with European Union and British flags reflecting Brexit and restrictions in export and import
Investing Articles

FTSE 100 investors should pay attention to these 4 things in September 2024

| Charlie Carman

Charlie Carman explores four key factors for UK investors to monitor this month that will influence the future direction of…

Read more »

Investing Articles

4 stocks that might power the FTSE 100 towards 10,000

| John Fieldsend

The FTSE 100 has been flirting with its all-time high again. Could it break through and hit that magical 10,000…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

As AstraZeneca reaches a 52-week high, is this still a top UK stock to consider?

| Ben McPoland

Ben McPoland takes a look at the largest UK stock by market cap to assess whether it might be overvalued…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

5 FTSE stocks Fools think will lead the next bull market charge

| The Motley Fool Staff

Savvy Fools will know the time to be buying the best FTSE stocks isn’t when a new bull market is…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Up 38% from its 12-month low, how can AstraZeneca’s share price still look cheap?

| Simon Watkins

Despite its big rise over the year, AstraZeneca’s share price still looks very undervalued to me, supported by strong H1…

Read more »

A black male doctor chats to a senior patient on the hospital ward ,with a young female nurse wearing a hijab attending to a dressing
Investing Articles

AstraZeneca hits £200bn as its share price soars. Can I afford to miss out?

| Alan Oscroft

The AstraZeneca share price is up 17% so far this year. But now the firm has broken the £200bn barrier,…

Read more »

Investing Articles

If I had £5k to invest in August, I’d buy these 2 top FTSE 100 stocks

| Ben McPoland

This writer highlights a growth-oriented pair of FTSE 100 stocks that he thinks look poised to deliver long-term growth for…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

No savings at 40? I’d buy cheap UK shares to retire richer

| Zaven Boyrazian, CFA

Buying cheap UK shares can have a profound impact on long-term wealth, even when starting later in life. Zaven Boyrazian…

Read more »

UK supporters with flag
Investing Articles

AstraZeneca, a mega-cap growth stock that just got cheaper!

| Dr. James Fox

Our writer takes a closer look at this growth stock -- which also happens to be the largest company of…

Read more »

Engineer Project Manager Talks With Scientist working on Computer
Investing Articles

The AstraZeneca share price dips as the company raises full-year guidance!

| Kevin Godbold

AstraZeneca's biopharmaceutical business is delivering ongoing growth, so share price weakness now may be a buying opportunity.

Read more »

Female Doctor In White Coat Having Meeting With Woman Patient In Office
Investing Articles

Here’s why H1 results could boost the AstraZeneca share price

| Alan Oscroft

The AstraZeneca share price has been a success story in the past five years. With H1 results due, can it…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

As AstraZeneca’s share price dips 4%, is it time for me to buy more?

| Simon Watkins

Despite its 12-month increase, AstraZeneca’s share price appears very undervalued to me, and looks set to rise on strong growth…

Read more »